Abstract:Intrahepatic cholangiocarcinoma (ICC), the second most common primary liver cancer, is a fatal malignancy with a poor prognosis and only very limited therapeutic options. Although molecular targeted therapy is emerged as a promising treatment strategy, resistance to molecular-targeted therapy occurs inevitably, which represents a major clinical challenge. In this study, we confirmed that mammalian target of rapamycin (mTOR) signaling is the most significantly affected pathways in ICC. As a novel phosphoinositide 3-kinase (PI3K)/mTOR dual inhibitor, BEZ235, exerts antitumour activity by effectively and specifically blocking the dysfunctional activation of the PI3K/serine/threonine kinase (AKT)/mTOR pathway. We generate the orthotopic ICC mouse model through hydrodynamic transfection of AKT and yes-associated protein (YAP) plasmids into the mouse liver. Our study confirmed that BEZ235 can suppress the proliferation, invasion and colony conformation abilities of ICC cells in vitro but cannot effectively inhibit ICC progression in vivo. Inhibition of PI3K/mTOR allowed upregulation of c-Myc and YAP through suppressed the phosphorylation of LATS1. It would be a novel mechanism that mediated resistance to PI3K/mTOR dual inhibitor. However, Bromo- and extraterminal domain (BET) inhibition by JQ1 downregulates c-Myc and YAP transcription, which could enhance the efficacy of PI3K/mTOR inhibitors. The efficacy results of combination therapy exhibited effective treatment on ICC in vitro and in vivo. Our data further confirmed that the combination of PI3K/mTOR dual inhibitor and BET inhibition induces M1 polarization and suppresses M2 polarization in macrophages by regulating the expression of HIF-1α. Our study provides a novel and efficient therapeutic strategy in treating primary ICC.

Catalytic-independent functions of INTAC in conferring sensitivity to BET inhibition

BET Protein Inhibition Evidently Enhances Sensitivity to PI3K/mTOR Dual Inhibition in Intrahepatic Cholangiocarcinoma

KDM5C-mediated recruitment of BRD4 to chromatin regulates enhancer activation and BET inhibitor sensitivity

The mechanisms behind the therapeutic activity of BET bromodomain inhibition

INTAC endonuclease and phosphatase modules differentially regulate transcription by RNA polymerase II

An Acetyl-Histone Vulnerability in PI3K/AKT Inhibition-Resistant Cancers is Targetable by Both BET and HDAC Inhibitors

Targeting the epigenetic reader ENL inhibits super-enhancer-driven oncogenic transcription and synergizes with BET inhibition to suppress tumor progression

HDAC8 Enhances the Function of HIF-2α by Deacetylating ETS1 to Decrease the Sensitivity of TKIs in ccRCC

Achieving clinical success with BET inhibitors as anti-cancer agents

Acetyl-CoA biosynthesis drives resistance to histone acetyltransferase inhibition

Tuning Transcription Factor Availability through Acetylation-Mediated Genomic Redistribution

Genome-wide CRISPR/Cas9 Screening Identifies Determinant of Panobinostat Sensitivity in Acute Lymphoblastic Leukemia

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.

Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development

NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model

Functional Investigations of p53 Acetylation Enabled by Heterobifunctional Molecules

Selective inhibition of BET bromodomains

Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains

Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy

Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes